Back to companies

Ascendis Pharma AS: Premium Databases

Ascendis Pharma AS Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

A sample of Ascendis Pharma AS Regulatory Milestones data

Drug Name Generic Name Brand Name Company Name Expiry Geography Constraining Patent Number Constraining Patent Expiry Drug Expiry (Estimated) Highest Development Stage
Showing 3 of 4 results.
Deserunt mollit sunt Lorem Lorem Lorem Pfizer Inc Lorem WXYZ Lorem Pending Lorem
ACP-015 - - Ascendis Pharma AS Japan JP5588354 Jan-2029 - -
ACP-015 - - Ascendis Pharma AS United States US8906847 Apr-2031 - Phase II
ACP-015 - - Ascendis Pharma AS EU EP2237799 Jan-2029 - Phase II

A sample of Ascendis Pharma AS Review Designation data

Drug Name Generic Name Company Name Indication Geography Designation Type Designation Status Designation Date
Showing 3 of 4 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore Lorem Pfizer Inc Lorem Lorem Lorem Lorem 31 Oct 2022
ACP-015 - Ascendis Pharma AS Achondroplasia United States Orphan Drug Designation Designated 27 Feb 2019
palopegteriparatide palopegteriparatide Ascendis Pharma AS Hypoparathyroidism United States Priority Review Designated 31 Oct 2022
palopegteriparatide palopegteriparatide Ascendis Pharma AS Hypoparathyroidism Japan Orphan Drug Designation Designated 21 Jun 2021
Regulatory Milestones

Feature

Regulatory Milestones provides an interactive, comprehensive, and analytical view of Drug and Constraining Patent Expiry and Exclusivity for Marketed and Pipeline (till preclinical development stage) pharmaceutical drugs in the United States (US), Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

Benefit

Regulatory Milestones provides patent information for all novel Marketed and Pipeline pharmaceutical drugs available in the US, Europe (United Kingdom, Germany, France, Italy, and Spain) and Japan.

The Drug Expiry filters include Expiry Geography and Expiry Date as well as US-specific information.

The Drug Expiry date is based on the Constraining Patent Expiry, Patent Term Extension or Supplementary Protection Certificate (depending on the regulator), Exclusivity analysis and specific information on Review Designations granted by regulators.

US-specific information includes Exclusivity Type and Paragraph IV Certification filing under the Hatch Waxman Act (Paragraph IV).

Value

Regulatory Milestones is easily accessible and features a user-friendly platform. The tool includes attributes relating to Drug Expiry and Constraining Patents as well as attributes from Drugs and Companies .

Clients can utilize Regulatory Milestones to save time and effort through accumulated expiry information from various sources and registries in a standardized comparable format.

Premium databases is part of our industry range of products

Gain a 360-degree view of Ascendis Pharma AS and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward